{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:55:07Z","timestamp":1790848507374,"version":"4.1.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":86,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001922","name":"Efficacy and Mechanism Evaluation Programme","doi-asserted-by":"publisher","award":["NIHR 132299"],"award-info":[{"award-number":["NIHR 132299"]}],"id":[{"id":"10.13039\/501100001922","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cystic fibrosis-related diabetes (CFrD) is a common complication of cystic fibrosis (CF). Many people with CFrD struggle to keep glucose within target range leading to poorer clinical outcomes and reduced life expectancy. Hybrid closed-loop (HCL) systems are an exciting innovation which may help people with CFrD improve their glucose management and experience a better quality-of-life. We explored the experiences of adults with CFrD who used the CamAPS FX HCL to: understand the benefits and challenges to using HCL in people with CFrD; and, help inform decision-making about HCL use in CFrD populations in routine clinical care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We interviewed 19 individuals who used the CamAPS FX HCL for \u2265\u20093 months during the CL4P-CF clinical trial. Data were analysed thematically.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Participants reported multiple clinical and quality-of-life benefits to using HCL. Many described treatment burnout before using the system and, hence, benefitting from automated glucose regulation and an increased capacity to take on new activities. Participants also shared historical difficulties gaining\/maintaining weight as a result of their CF and described how using the system helped them achieve weight\/muscle gain, improved their bodily confidence and enabled to them to enjoy a greater diversity of foods. Participants also observed CF-related benefits, including a (perceived) reduced susceptibility to infections, improved mood\/energy to take on CF management-tasks, and increased confidence and ability to undertake physical activity due to a reduced risk of hypoglycaemia. In addition, participants reported medical trauma arising from hospital admissions in childhood and exposure to medically-invasive procedures for their CF, and highlighted benefits to using a system which mitigated the need to use injections. Due to their earlier traumatic experiences, some expressed a preference for using tubeless pumps and cannulas that require less frequent replacement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Participants reported improved glucose management, CF-related benefits and wide-ranging quality-of-life gains resulting from HCL use. Given their earlier experiences of treatment burnout and medically-related trauma, and taking account of the distinctive challenges involved in managing CFrD, our findings suggest that people with CFrD are a uniquely deserving group for access to HCL technology if shown to be clinically and cost effective in this population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov: NCT05562492, registration date 28th September 2022.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12902-026-02360-5","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T16:06:08Z","timestamp":1783440368000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Participants\u2019 experiences of living with cystic fibrosis related diabetes and using a hybrid closed-loop system to support self-management: qualitative study"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8016-7374","authenticated-orcid":false,"given":"Julia","family":"Lawton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2797-3385","authenticated-orcid":false,"given":"Amanda I.","family":"Adler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9541-2221","authenticated-orcid":false,"given":"Amanda","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8911-6744","authenticated-orcid":false,"given":"Richard I. G.","family":"Holt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2901-461X","authenticated-orcid":false,"given":"Roman","family":"Hovorka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4285-4656","authenticated-orcid":false,"given":"Nithya","family":"Kadiyala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7499-0439","authenticated-orcid":false,"given":"Marian","family":"Peacock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3272-9544","authenticated-orcid":false,"given":"Charlotte K.","family":"Boughton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5835-3402","authenticated-orcid":false,"given":"David","family":"Rankin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"2360_CR1","unstructured":"Naito Y, Adams F, Charman S, Duckers J, Davies G, Clarke S. Sep. UK Cystic Fibrosis Registry 2023 annual data report. London: Cystic Fibrosis Trust; 2024. Available from: https:\/\/www.cysticfibrosis.org.uk\/sites\/default\/files\/2024-11\/CFT_2023_Annual_Data_Report_Oct2024%201.pdf.\u00a0Accessed 2025 Sep 3."},{"key":"2360_CR2","unstructured":"Welsh M, Ramsey BW, Accurso FJ, Cutting GR. Cystic fibrosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Vogelstein B, editors. The metabolic and molecular basis of inherited disease. 8th ed. New York (NY): McGraw-Hill; 2001. p. 5121-88."},{"key":"#cr-split#-2360_CR3.1","unstructured":"UK Cystic Fibrosis Registry. Cystic Fibrosis: Strength in Numbers. Annual Data Report 2019 [Internet]. London: Cystic Fibrosis Trust"},{"key":"#cr-split#-2360_CR3.2","unstructured":"2020 [cited 2025 Sep 3]. Available from: https:\/\/www.cysticfibrosis.org.uk\/sites\/default\/files\/2020-12\/2019%20Registry%20Annual%20Data%20report_Sep%202020.pdf."},{"issue":"10059","key":"2360_CR4","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","volume":"388","author":"JS Elborn","year":"2016","unstructured":"Elborn JS. Cystic fibrosis. Lancet. 2016;388(10059):2519\u201331.","journal-title":"Lancet"},{"issue":"9","key":"2360_CR5","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.2337\/dc09-0586","volume":"32","author":"A Moran","year":"2009","unstructured":"Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W. Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care. 2009;32(9):1626\u201331.","journal-title":"Diabetes Care"},{"key":"2360_CR6","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes\u20142021. Diabetes Care. 2021;44(Suppl_1):S15-S33.","DOI":"10.2337\/dc21-S002"},{"issue":"9","key":"2360_CR7","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1111\/dme.13652","volume":"35","author":"N Bridges","year":"2018","unstructured":"Bridges N, Rowe R, Holt RIG. Unique challenges of cystic fibrosis-related diabetes. Diabet Med. 2018;35(9):1181\u201388.","journal-title":"Diabet Med"},{"issue":"2","key":"2360_CR8","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.jcf.2017.11.019","volume":"17","author":"RH Keogh","year":"2018","unstructured":"Keogh RH, Szczesniak R, Taylor-Robinson D, Bilton D. Up-to-date and projected estimates of survival for people with cystic fibrosis using baseline characteristics: A longitudinal study using UK patient registry data. J Cyst Fibros. 2018;17(2):218.","journal-title":"J Cyst Fibros"},{"issue":"2","key":"2360_CR9","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jcf.2006.03.009","volume":"6","author":"AL Brennan","year":"2007","unstructured":"Brennan AL, Gyi KM, Wood DM, Johnson J, Holliman R, Baines DL, et al. Airway glucose concentrations and effect on growth of respiratory pathogens in cystic fibrosis. J Cyst Fibros. 2007;6(2):101\u20139.","journal-title":"J Cyst Fibros"},{"issue":"12","key":"2360_CR10","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.2337\/dc10-1768","volume":"33","author":"A Moran","year":"2010","unstructured":"Moran A, Brunzell C, Cohen RC, Katz M, Marshall BC, Onady G, et al. Clinical care guidelines for cystic fibrosis\u2013related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care. 2010;33(12):2697\u2013708.","journal-title":"Diabetes Care"},{"key":"2360_CR11","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1183\/16000617.0293-2020","volume":"30","author":"BJ Prentice","year":"2021","unstructured":"Prentice BJ, Jaffe A, Hameed S, Verge CF, Waters S, Widger J. Cystic fibrosis-related diabetes and lung disease: an update. Eur Respir Rev. 2021;30:159.","journal-title":"Eur Respir Rev"},{"key":"2360_CR12","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3389\/fendo.2018.00020","volume":"9","author":"K Kayani","year":"2018","unstructured":"Kayani K, Mohammed R, Mohiaddin H. Cystic fibrosis-related diabetes. Front Endocrinol. 2018;9:20.","journal-title":"Front Endocrinol"},{"issue":"4","key":"2360_CR13","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.jpeds.2007.09.025","volume":"152","author":"E Bismuth","year":"2008","unstructured":"Bismuth E, Laborde K, Taupin P, Velho G, Ribault V, Jennane F, et al. Glucose tolerance and insulin secretion, morbidity, and death in patients with cystic fibrosis. J Pediatr. 2008;152(4):540\u201345.","journal-title":"J Pediatr"},{"issue":"7","key":"2360_CR14","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.2337\/dc10-2289","volume":"34","author":"AI Adler","year":"2011","unstructured":"Adler AI, Shine B, Haworth C, Leelarathna L, Bilton D. Hyperglycemia and death in cystic fibrosis-related diabetes. Diabetes Care. 2011;34(7):1577\u20138.","journal-title":"Diabetes Care"},{"issue":"8","key":"2360_CR15","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1111\/pedi.13453","volume":"23","author":"KL Ode","year":"2022","unstructured":"Ode KL, Ballman M, Battezzati A, Brennan A, Chan CL, Hameed S, et al. ISPAD Clinical Practice Consensus Guidelines 2022: management of cystic fibrosis-related diabetes in children and adolescents. Pediatr Diabetes. 2022;23(8):1212.","journal-title":"Pediatr Diabetes"},{"issue":"3","key":"2360_CR16","first-page":"100","volume":"1","author":"K Millington","year":"2014","unstructured":"Millington K, Miller V, Rubenstein RC, Kelly A. Patient and parent perceptions of the diagnosis and management of cystic fibrosis-related diabetes. J Clin Transl Endocrinol. 2014;1(3):100\u20137.","journal-title":"J Clin Transl Endocrinol"},{"issue":"7b","key":"2360_CR17","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/j.1365-2702.2008.02331.x","volume":"17","author":"S Tierney","year":"2008","unstructured":"Tierney S, Deaton C, Webb K, Jones A, Dodd M, McKenna D, et al. Isolation, motivation and balance: living with type 1 or cystic fibrosis-related diabetes. J Clin Nurs. 2008;17(7b):235\u201343.","journal-title":"J Clin Nurs"},{"issue":"8","key":"2360_CR18","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1177\/17449871221116970","volume":"27","author":"S Collins","year":"2022","unstructured":"Collins S, Jones A, Woodward S, Sturt J. The experience of living with and managing cystic fibrosis related diabetes: A qualitative review. J Res Nurs. 2022;27(8):735\u201353.","journal-title":"J Res Nurs"},{"issue":"5","key":"2360_CR19","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.jcf.2019.03.007","volume":"18","author":"E Kwong","year":"2022","unstructured":"Kwong E, Desai S, Chong L, Lee K, Zheng J, Wilcox PG, et al. The impact of cystic fibrosis-related diabetes on health-related quality of life. J Cyst Fibros. 2022;18(5):734\u201336.","journal-title":"J Cyst Fibros"},{"issue":"1","key":"2360_CR20","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jcf.2019.08.002","volume":"19","author":"JS Sherwood","year":"2020","unstructured":"Sherwood JS, Jafri RZ, Balliro CA, Zheng H, El-Khatib FH, Damiano ET, et al. Automated glycemic control with the bionic pancreas in cystic fibrosis-related diabetes: a pilot study. J Cyst Fibros. 2020;19(1):159\u201361.","journal-title":"J Cyst Fibros"},{"issue":"1","key":"2360_CR21","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2337\/dc23-1411","volume":"47","author":"JS Sherwood","year":"2024","unstructured":"Sherwood JS, Castellanos LE, O\u2019Connor MY, Balliro CA, Hillard MA, Gaston SG, et al. Randomized Trial of the Insulin-Only iLet Bionic Pancreas for the Treatment of Cystic Fibrosis- Related Diabetes. Diabetes Care. 2024;47(1):101\u20138.","journal-title":"Diabetes Care"},{"key":"2360_CR22","doi-asserted-by":"publisher","first-page":"1347141","DOI":"10.3389\/fendo.2024.1347141","volume":"15","author":"M Bassi","year":"2024","unstructured":"Bassi M, Franzone D, Dufour F, Spacco G, Cresta F, d\u2019Annunzio G, et al. Efficacy of advanced hybrid closed loop systems in cystic fibrosis related diabetes: a pilot study. Front Endocrinol (Lausanne). 2024;15:1347141.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"2360_CR23","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1089\/dia.2021.0354","volume":"24","author":"KJ Scully","year":"2022","unstructured":"Scully KJ, Palani G, Zheng H, Moheet A, Putman MS. The effect of control IQ hybrid closed loop technology on glycemic control in adolescents and adults with cystic fibrosis-related diabetes. Diabetes Technol Ther. 2022;24(6):446\u201352.","journal-title":"Diabetes Technol Ther"},{"key":"2360_CR24","unstructured":"Kadiyala N, Coleman RL, Lakshman R, Wilinska ME, Brennan A, Lumb A, et al. Assessing the efficacy, safety and utility of hybrid closed-loop glucose control compared to standard insulin therapy combined with glucose sensor in young people (\u2265 16 years) and adults with cystic fibrosis related diabetes (CL4P-CF study): protocol for an open-label, multi-centre, randomised, two arm and single period superiority parallel trial. Under review at BMJ Open."},{"issue":"6","key":"2360_CR25","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","volume":"19","author":"A Tong","year":"2007","unstructured":"Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349\u201357.","journal-title":"Int J Qual Health Care"},{"key":"2360_CR26","doi-asserted-by":"publisher","first-page":"175346662412978","DOI":"10.1177\/17534666241297877","volume":"18","author":"L Somerville","year":"2024","unstructured":"Somerville L, Borish L, Noth I, Albon D. Modulator-refractory cystic fibrosis: Defining the scope and challenges of an emerging at-risk population. Ther Adv Respir Dis. 2024;18:17534666241297877.","journal-title":"Ther Adv Respir Dis"},{"issue":"4","key":"2360_CR27","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1177\/1359105317718615","volume":"25","author":"ML Tanenbaum","year":"2020","unstructured":"Tanenbaum ML, Iturralde E, Hanes SJ, Suttiratana SC, Ambrosino JM, Ly TT, et al. Trust in hybrid closed loop among people with diabetes: Perspectives of experienced system users. J Health Psychol. 2020;25(4):429\u201338.","journal-title":"J Health Psychol"},{"issue":"3","key":"2360_CR28","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1089\/dia.2018.0306","volume":"21","author":"J Lawton","year":"2019","unstructured":"Lawton J, Blackburn M, Rankin D, Allen JM, Campbell FM, Leelarathna L, et al. Participants\u2019 experiences of, and views about, daytime use of a day-and-night hybrid closed-loop system in real life settings: longitudinal qualitative study. Diabetes Technol Ther. 2019;21(3):119\u201327.","journal-title":"Diabetes Technol Ther"},{"issue":"1","key":"2360_CR29","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jcf.2024.11.003","volume":"24","author":"RS Everhart","year":"2025","unstructured":"Everhart RS, McWilliams E, Maggs J, Sawicki GS, Sconiers T, Smith K, et al. What does it mean to be healthy when taking elexacaftor\/tezacaftor\/ivacaftor (ETI)? A qualitative study. J Cyst Fibros. 2025;24(1):187\u201392.","journal-title":"J Cyst Fibros"},{"issue":"6","key":"2360_CR30","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/dme.13887","volume":"36","author":"J Lawton","year":"2018","unstructured":"Lawton J, Blackburn M, Rankin D, Allen J, Campbell F, Leelarathna L, et al. The impact of using a closed-loop system on food choices and eating practices among people with type 1 diabetes: a qualitative study involving adults, teenagers and parents. Diabet Med. 2018;36(6):753\u201360.","journal-title":"Diabet Med"},{"issue":"12","key":"2360_CR31","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1089\/dia.2023.0323","volume":"25","author":"J Lawton","year":"2023","unstructured":"Lawton J, Kimbell B, Closs M, Hartnell S, Lee TTM, Dover AR, et al. Listening to Women: Experiences of Using Closed-Loop in Type 1 Diabetes Pregnancy. Diabetes Technol Ther. 2023;25(12):845\u201355.","journal-title":"Diabetes Technol Ther"},{"issue":"4","key":"2360_CR32","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1177\/1742395320985924","volume":"18","author":"D Rankin","year":"2021","unstructured":"Rankin D, Kimbell B, Hovorka R, Lawton J. Adolescents\u2019 and their parents\u2019 experiences of using a closed-loop system to manage type 1 diabetes in everyday life: qualitative study. Chronic Illn. 2021;18(4):742\u201356.","journal-title":"Chronic Illn"},{"issue":"5","key":"2360_CR33","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1177\/1932296821994201","volume":"15","author":"D Rankin","year":"2021","unstructured":"Rankin D, Kimbell B, Allen JM, Besser RE, Boughton CK, Campbell F, et al. Adolescents\u2019 Experiences of Using a Smartphone Application Hosting a Closed-loop Algorithm to Manage Type 1 Diabetes in Everyday Life: Qualitative Study. J Diabetes Sci Technol. 2021;15(5):1042\u201351.","journal-title":"J Diabetes Sci Technol"},{"key":"2360_CR34","doi-asserted-by":"publisher","first-page":"109877","DOI":"10.1016\/j.diabres.2022.109877","volume":"187","author":"B Kimbell","year":"2022","unstructured":"Kimbell B, Rankin D, Hart RI, Allen JM, Boughton CK, Campbell F, et al. Parents\u2019 experiences of using a hybrid closed-loop system (CamAPS FX) to care for a very young child with type 1 diabetes: qualitative study. Diabetes Res Clin Pract. 2022;187:109877.","journal-title":"Diabetes Res Clin Pract"},{"issue":"2","key":"2360_CR35","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77\u2013101.","journal-title":"Qual Res Psychol"},{"issue":"1","key":"2360_CR36","doi-asserted-by":"publisher","first-page":"pe15449","DOI":"10.1111\/dme.15449","volume":"42","author":"JY Wong","year":"2025","unstructured":"Wong JY, Styles SE, Wiltshire EJ, de Bock MI, Boucsein A, Palmer OJ, et al. Experiences of adolescents and young adults with type 1 diabetes and chronically elevated glucose levels following the transition from multiple daily injections to advanced hybrid closed-loop: a qualitative study. Diabet Med. 2025;42(1):pe15449.","journal-title":"Diabet Med"},{"issue":"4","key":"2360_CR37","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1089\/dia.2023.0394","volume":"26","author":"R Lakshman","year":"2024","unstructured":"Lakshman R, Hartnell S, Ware J, Allen JM, Wilinska ME, Nwokolo M, et al. Lived experience of fully closed-loop insulin delivery in adults with type 1 diabetes. Diabetes Technol Ther. 2024;26(4):211\u201321.","journal-title":"Diabetes Technol Ther"},{"issue":"2","key":"2360_CR38","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1177\/0145721717697244","volume":"43","author":"E Iturralde","year":"2017","unstructured":"Iturralde E, Tanenbaum ML, Hanes SJ, Suttiratana SC, Ambrosino JM, Ly TT, et al. Expectations and attitudes of individuals with type 1 diabetes after using a hybrid closed-loop system. Diabetes Educ. 2017;43(2):223\u201332.","journal-title":"Diabetes Educ"},{"issue":"1","key":"2360_CR39","doi-asserted-by":"publisher","first-page":"e001420","DOI":"10.1136\/bmjresp-2022-001420","volume":"9","author":"M Almulhem","year":"2022","unstructured":"Almulhem M, Harnett N, Graham S, Haq I, Visram S, Ward C, et al. Exploring the impact of elexacaftor-tezacaftor-ivacaftor treatment on opinions regarding airway clearance techniques and nebulisers: TEMPO a qualitative study in children with cystic fibrosis, their families and healthcare professionals. BMJ Open Respir Res. 2022;9(1):e001420.","journal-title":"BMJ Open Respir Res"},{"key":"2360_CR40","doi-asserted-by":"publisher","first-page":"204062232412644","DOI":"10.1177\/20406223241264477","volume":"15","author":"M Basile","year":"2024","unstructured":"Basile M, Polo J, Henthorne K, DeCelie-Germana J, Galvin S, Wang J. The impact of elexacaftor\/tezacaftor\/ivacaftor on cystic fibrosis health-related quality of life and decision-making about daily treatment regimens: a mixed methods exploratory study. Ther Adv Chronic Dis. 2024;15:20406223241264477.","journal-title":"Ther Adv Chronic Dis"},{"issue":"1","key":"2360_CR41","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12912-025-02774-x","volume":"24","author":"U Skogeland","year":"2025","unstructured":"Skogeland U, de Monestrol I, Pincikova T, Godskesen T. Lived experiences for individuals with cystic fibrosis who have undergone lung transplantation: a qualitative study. BMC Nurs. 2025;24(1):127.","journal-title":"BMC Nurs"},{"key":"2360_CR42","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.jcf.2019.08.016","volume":"18","author":"A Granados","year":"2019","unstructured":"Granados A, Chan CL, Ode KL, Moheet A, Moran A, Holl R. Cystic fibrosis related diabetes: Pathophysiology, screening and diagnosis. J Cyst Fibros. 2019;18:S3\u20139.","journal-title":"J Cyst Fibros"},{"issue":"3","key":"2360_CR43","doi-asserted-by":"publisher","first-page":"e12878","DOI":"10.1111\/petr.12878","volume":"21","author":"SM Anderson","year":"2017","unstructured":"Anderson SM, Wray J, Ralph A, Spencer H, Lunnon-Wood T, Gannon K. Experiences of adolescent lung transplant recipients: A qualitative study. Pediatr Transpl. 2017;21(3):e12878.","journal-title":"Pediatr Transpl"},{"key":"2360_CR44","first-page":"35","volume":"54","author":"R Dobra","year":"2025","unstructured":"Dobra R, Carroll S, Davies JC, Dowdall F, Duff A, Elderton A, et al. Exploring the complexity of cystic fibrosis (CF) and psychosocial wellbeing in the 2020s: Current and future challenges. Pediatr Respir Rev. 2025;54:35\u201342.","journal-title":"Pediatr Respir Rev"},{"key":"2360_CR45","doi-asserted-by":"publisher","first-page":"S36","DOI":"10.1002\/ppul.26870","volume":"59","author":"ER Lyons","year":"2024","unstructured":"Lyons ER, Muther E, Sabharwal S. Nutrition and behavioral health in cystic fibrosis: Eating and body image. Pediatr Pulmonol. 2024;59:S36\u201343.","journal-title":"Pediatr Pulmonol"},{"issue":"3","key":"2360_CR46","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.jcf.2023.10.012","volume":"23","author":"R Patil","year":"2024","unstructured":"Patil R, Magaret AS, Jain R, Taylor-Cousar J, Hughan KS, Kazmerski TM. Factors associated with pubertal growth outcomes in cystic fibrosis: Early Growth and Puberty in CF. J Cyst Fibros. 2024;23(3):538\u201344.","journal-title":"J Cyst Fibros"},{"issue":"1","key":"2360_CR47","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1519\/SSC.0000000000000641","volume":"44","author":"CJ Holmes","year":"2022","unstructured":"Holmes CJ, Granados A. Resistance Training Recommendations for Children and Adolescents With Cystic Fibrosis\u2013Related Diabetes. Strength Cond J. 2022;44(1):111\u201318.","journal-title":"Strength Cond J"},{"key":"2360_CR48","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-P\u00e9rez-de-Sevilla G, Yvert T, Blanco \u00c1, Sosa Pedreschi AI, Thuissard IJ, P\u00e9rez-Ruiz M. Effectiveness of physical exercise interventions on pulmonary function and physical fitness in children and adults with cystic fibrosis: a systematic review with meta-analysis. Healthcare (Basel). 2022;10(11):2205.","DOI":"10.3390\/healthcare10112205"},{"issue":"2","key":"2360_CR49","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jcf.2018.02.006","volume":"17","author":"C Castellani","year":"2018","unstructured":"Castellani C, Duff AJ, Bell SC, Heijerman HG, Munck A, Ratjen F, et al. ECFS best practice guidelines: the 2018 revision. J Cyst Fibros. 2018;17(2):153\u201378.","journal-title":"J Cyst Fibros"},{"issue":"4","key":"2360_CR50","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.jcf.2022.12.008","volume":"22","author":"AA Cuneo","year":"2023","unstructured":"Cuneo AA, Outram S, Marsac ML, Vendlinski S, Heyman MB, Ly N, et al. Medical traumatic stress in cystic fibrosis: A qualitative analysis. J Cyst Fibros. 2023;22(4):763\u201371.","journal-title":"J Cyst Fibros"},{"issue":"Pt 2","key":"2360_CR51","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1348\/135910710X506895","volume":"16","author":"S Ayers","year":"2011","unstructured":"Ayers S, Muller I, Mahoney L, Seddon P. Understanding needle-related distress in children with cystic fibrosis. Br J Health Psychol. 2011;16(Pt 2):329\u201343.","journal-title":"Br J Health Psychol"},{"issue":"7","key":"2360_CR52","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1002\/ppul.26419","volume":"58","author":"H Kimball","year":"2023","unstructured":"Kimball H, Cobham VE, Sanders M, Douglas T. Procedural anxiety among children and adolescents with cystic fibrosis and their parents. Pediatr Pulmonol. 2023;58(7):1967\u201376.","journal-title":"Pediatr Pulmonol"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-026-02360-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-026-02360-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-026-02360-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:02:49Z","timestamp":1790845369000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12902-026-02360-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2360"],"URL":"https:\/\/doi.org\/10.1186\/s12902-026-02360-5","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"assertion":[{"value":"6 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the East of England- Cambridge South Research Ethics Committee (UK) (#22\/EE\/0164) and was conducted in accordance with the declaration of Helsinki. All participants were provided with verbal and written information about the trial and procedures involved in the (interview) study and gave their written informed consent prior to participation.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants gave their consent for data to be used in publications arising from this study.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"RH reports having received speaker honoraria from Eli Lilly, Dexcom and Novo Nordisk, receiving license fees from Braun; receiving consultancy fees from Abbott Diabetes Care, patents related to closed-loop, and being director at CamDiab. CKB has received consultancy fees from CamDiab, speaker honoraria from Ypsomed and research support from Abbott Diabetes Care, Dexcom and Ypsomed. All other authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"297"}}